Plain-English translation of NCT07744256 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new type of cell therapy called CAR-NK cells that are grown from healthy donor cells and engineered to attack small cell lung cancer. The medication is designed to recognize and destroy cancer cells that have specific markers on their surface. Researchers will test three different versions of this treatment to see which works best and is safest.
Small cell lung cancer is aggressive and often comes back or stops responding to standard chemotherapy. The new treatment aims to give patients another option by using their own immune system to fight the cancer in a new way.
You likely qualify if…
You likely don't qualify if…
You will first have tests to check your health and analyze your tumor to see which type of treatment is best for you. Then you will receive chemotherapy to prepare your body, followed by infusions of the engineered immune cells. You may receive multiple doses of the cells over several weeks, and you'll be closely monitored in the hospital for side effects like fever, confusion, or difficulty breathing. The trial involves regular blood tests, imaging scans, and clinic visits to track how well the treatment is working and to catch any problems early.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
China